1.
Bieber T, Beck L, Pink A, Saeki H, Eichenfeld L, Werfel T, Rosholm A, Ropke M, Paller A. Neutralizing interleukin-13 increases skin microbial diversity: results from a Phase 3, randomized, double-blind, placebo-controlled trial of tralokinumab in adult patients with atopic dermatitis. J of Skin [Internet]. 2021Nov.5 [cited 2022Aug.13];5(6):s56. Available from: https://jofskin.org/index.php/skin/article/view/1407